Document Detail

Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation.
MedLine Citation:
PMID:  16169656     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The aim of this study was to determine the maternal and umbilical vein soluble Fas and its ligand (sFasL) serum levels in pregnancies complicated by preeclampsia with intrauterine growth retardation (IUGR). PATIENTS AND METHODS: The study was carried out on 11 preeclamptic delivering patients in the third trimester of pregnancy with severe preeclampsia complicated by intrauterine growth retardation. The control group consisted of 12 healthy normotensive delivering patients with singleton uncomplicated pregnancies, without any renal, heart and vascular diseases and with normal laboratory tests. Maternal and umbilical serum soluble Fas and FasL concentrations were estimated using a sandwich ELISA assay. RESULTS AND CONCLUSIONS: Increased maternal and umbilical vein serum sFas and increased umbilical vein serum sFasL levels were found in the study group in comparison with the control group. In our study in both groups of patient higher maternal sFas values were observed in comparison with the umbilical cord blood. Further studies are necessary to evaluate the role of Fas/FasL pathway in pregnancies complicated by preeclampsia and intrauterine growth retardation.
Marzena Laskowska; Katarzyna Laskowska; Bozena Leszczyńska-Gorzelak; Jan Oleszczuk
Related Documents :
3286866 - Specific therapy in severe fetal intrauterine growth retardation: failure of prostacyclin.
4050296 - Human placental lactogen and du-estrogen levels in normal twin pregnancies.
15068936 - A review of the literature on the effects of ambient air pollution on fetal growth.
3042016 - Patterns of growth of uterine leiomyomas during pregnancy. a prospective longitudinal s...
7369936 - Fetoscopy. a new technique for antenatal intrauterine diagnosis.
21624036 - Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a natio...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-09-19
Journal Detail:
Title:  European journal of obstetrics, gynecology, and reproductive biology     Volume:  126     ISSN:  0301-2115     ISO Abbreviation:  Eur. J. Obstet. Gynecol. Reprod. Biol.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-29     Completed Date:  2006-08-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375672     Medline TA:  Eur J Obstet Gynecol Reprod Biol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  155-9     Citation Subset:  IM    
Department of Obstetrics and Perinatology, University School of Medicine in Lublin, Lublin, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD95 / blood*
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Fas Ligand Protein
Fetal Blood / metabolism
Fetal Growth Retardation / blood,  physiopathology*
Membrane Glycoproteins / blood*
Pre-Eclampsia / blood,  physiopathology*
Tumor Necrosis Factors / blood*
Reg. No./Substance:
0/Antigens, CD95; 0/FASLG protein, human; 0/Fas Ligand Protein; 0/Membrane Glycoproteins; 0/Tumor Necrosis Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy of composite surface sealers in sealing cavosurface marginal gaps.
Next Document:  Tissue integration and tolerance to meshes used in gynecologic surgery: an experimental study.